Bloomberg News

Roche’s Perjeta for Breast Cancer Wins Approval

June 11, 2012

(Corrects drug spelling in headline, second paragraph of story published June 8.)

Roche Holding AG (ROG)’s personalized drug treatment for a fast-growing type of breast cancer won approval from U.S. regulators.

Perjeta, chemically known as pertuzumab, is designed to work with the Basel, Switzerland-based company’s Herceptin and chemotherapy to attack breast cancer that has spread in patients who have a certain gene mutation. The Food and Drug Administration today cleared Perjeta for consumer use, Roche’s Genentech unit said in a statement.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net.

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net


Soul Searcher
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus